keyboard_arrow_up

Competitor Analysis: IDO & TDO Inhibitors-Novel Immune Response Checkpoint Modulators

Competitor Analysis: IDO & TDO Inhibitors-Novel Immune Response Checkpoint Modulators is a new market research publication announced by Reportstack. The Competitive Intelligence report aboutIDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

To access full report with TOC, please visit  Competitor Analysis: IDO & TDO Inhibitors-Novel Immune Response Checkpoint Modulators.

The report provides a compilation of active small molecule projects in research and development as specific IDO or TDO inhibitors as well as dual IDO & TDO inhibitors for treatment of cancer. Competitor projects are listed in a tabular format providing information on:

Drug Codes
Target / Mechanism of Action
Class of Compound
Company
Product Category
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contact:

Debora White
Manager - Marketing 
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research